Latest Virotherapy Stories

A genetically reprogrammed Herpes simplex virus (HSV) can cure metastatic diffusion of human cancer cells in the abdomen of laboratory mice, according to a new study published January 31 in the Open Access journal PLOS Pathogens. The paper reports on the collaborative research from scientists at the at the University of Bologna and specifically describes that the HSV converted into a therapeutic anticancer agent attacks breast and ovarian cancer metastases. Past decades have witnessed...

HOUSTON, Oct. 23, 2012 /PRNewswire/ -- DNAtrix, Inc., the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products for brain cancer, announced today a merger with VectorLogics, Inc. (VLI), a company with a complementary intellectual property portfolio developing products for ovarian cancer. The merged company will retain the name DNAtrix and continue to develop its lead cancer product, DNX-2401, which is in clinical testing at the University...

CALGARY, June 13, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper entitled "Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients," has been published in the latest issue of the journal Science Translational Medicine (Vol. 4 Issue 138 138ra77). The paper covers findings from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in...

HELSINKI, Finland, May 29, 2012 /PRNewswire/ -- Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors. The first patients have already completed the safety assessment part of the study. "We are proud to be the first clinic in Northern Europe to start a clinical study with oncolytic viruses," comments the Principal Investigator...

  Researchers have engineered a virus that can selectively target cancer cells throughout the body. According to the team, the virus attacked only tumors during a small trial on 23 patients, leaving the healthy tissue alone. Researchers said the findings could one day "truly transform" therapies. Scientists modified the vaccinia virus, which is famous for being used to develop a smallpox vaccine. The virus is dependent on a chemical pathway in order to replicate. It was...

CALGARY, Aug. 2, 2011 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that an international team of researchers has reported on a study in the online version of Molecular Therapy, a publication of The American Society of Gene and Cell Therapy, investigating the timing of chemotherapy delivery that optimizes the efficacy of systemic REOLYSIN(®). The paper is entitled "Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for...

New research shows that oncolytic viruses, which are engineered to destroy cancer cells, might be more effective in treating deadly brain tumors if equipped with an enzyme that helps them penetrate the tumor.The enzyme, called chondroitinase, helps the cancer-killing virus clear its way through the thickets of protein molecules that fill space between cells and impede the virus's movement through the tumor, say researchers at the Ohio State University Comprehensive Cancer Center-Arthur G....

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice "“ still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.Less than 30 percent of patients with metastatic cancer survive beyond five years, despite the aggressive use of modern combination therapies, including chemotherapy. This creates a significant need for new sarcoma...

CINCINNATI, July 7 /PRNewswire-USNewswire/ -- Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice - still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy. Less than 30 percent of patients with metastatic cancer survive beyond five years, despite the aggressive use of modern combination therapies, including chemotherapy. This...

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research. The therapy program is based on scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.The results demonstrate an anti-tumor immunity of oncolytic viruses "“ published for the...